The stock of KemPharm Inc (NASDAQ:KMPH) is a huge mover today! About 90,652 shares traded hands or 83.21% up from the average. KemPharm Inc (NASDAQ:KMPH) has declined 67.48% since March 8, 2016 and is downtrending. It has underperformed by 76.80% the S&P500.
The move comes after 7 months positive chart setup for the $72.13 million company. It was reported on Oct, 11 by Barchart.com. We have $12.82 PT which if reached, will make NASDAQ:KMPH worth $116.13M more.
Analysts await KemPharm Inc (NASDAQ:KMPH) to report earnings on November, 10. They expect $-0.70 earnings per share, down 2.94% or $0.02 from last year’s $-0.68 per share. After $-0.58 actual earnings per share reported by KemPharm Inc for the previous quarter, Wall Street now forecasts 20.69% negative EPS growth.
KemPharm Inc (NASDAQ:KMPH) Ratings Coverage
Out of 4 analysts covering KemPharm (NASDAQ:KMPH), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $55 is the highest target while $14 is the lowest. The $32.75 average target is 567.01% above today’s ($4.91) stock price. KemPharm has been the topic of 6 analyst reports since August 14, 2015 according to StockzIntelligence Inc. Canaccord Genuity maintained it with “Buy” rating and $34 target price in Thursday, September 17 report. The firm earned “Outperform” rating on Friday, May 6 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, August 14. The stock has “Outperform” rating given by Oppenheimer on Friday, September 18.
According to Zacks Investment Research, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States.”
More notable recent KemPharm Inc (NASDAQ:KMPH) news were published by: Marketwatch.com which released: “KemPharm Inc. NASDAQ: KMPH” on April 16, 2015, also Prnewswire.com with their article: “KemPharm, Inc. Appoints Tracy M. Woody as Chief Commercial Officer” published on March 04, 2015, Fiercebiotech.com published: “Deerfield Management Company Announces a $60 Million Facility with KemPharm, Inc.” on June 03, 2014. More interesting news about KemPharm Inc (NASDAQ:KMPH) were released by: Businesswire.com and their article: “Zeldes Haeggquist & Eck, LLP Announces Investigation of KemPharm, Inc.” published on October 03, 2016 as well as Marketwatch.com‘s news article titled: “KemPharm shares drop as drug labeling contested by FDA committee” with publication date: May 05, 2016.
KMPH Company Profile
KemPharm, Inc., incorporated on May 28, 2014, is a clinical-stage specialty pharmaceutical company. The Firm is engaged in the discovery and development of prodrugs. The Firm uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Firm is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Firm has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Firm also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.